NEW
YORK, June 27, 2024 /PRNewswire/ -- The global
liposomal products market size is estimated to grow by USD 3.99 billion from 2024-2028, according to
Technavio. The market is estimated to grow at a CAGR of
10.87% during the forecast period. Rising incidence of
fungal disorders is driving market growth, with a trend towards
rising adoption of quality by design (QBD) over traditional
processes. However, inadequate reimbursement policies regarding
cancer treatment and liposomal products treatment poses a
challenge. Key market players include Acthera Therapeutics AG,
Bausch Lomb Corp., Baxter International Inc., Galen Ltd., GENFIT
SA, Gilead Sciences Inc., Innocan Pharma Corp. Ltd., Johnson and
Johnson Services Inc., Leadiant Biosciences Inc., Lipella
Pharmaceuticals Inc., Liposoma B.V., Merrimack Pharmaceuticals
Inc., Nanovex Biotechnologies SL, Pacira BioSciences Inc., Spectrum
Pharmaceuticals Inc., Taiwan Liposome Co. Ltd., Takeda
Pharmaceutical Co. Ltd., The Lubrizol Corp., Vascular Biosciences,
and Viatris Inc..
![Technavio has announced its latest market research report titled Global liposomal products market 2024-2028 Technavio has announced its latest market research report titled Global liposomal products market 2024-2028](https://mma.prnewswire.com/media/2448478/Technavio_Global_liposomal_products_market_2024_2028.jpg)
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Application (Cancer,
Fungal infections, Pain management, Viral vaccines, and
Photodynamic therapy), Type (Branded and Generic), and Geography
(North America, Europe, Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Acthera Therapeutics
AG, Bausch Lomb Corp., Baxter International Inc., Galen Ltd.,
GENFIT SA, Gilead Sciences Inc., Innocan Pharma Corp. Ltd., Johnson
and Johnson Services Inc., Leadiant Biosciences Inc., Lipella
Pharmaceuticals Inc., Liposoma B.V., Merrimack Pharmaceuticals
Inc., Nanovex Biotechnologies SL, Pacira BioSciences Inc., Spectrum
Pharmaceuticals Inc., Taiwan Liposome Co. Ltd., Takeda
Pharmaceutical Co. Ltd., The Lubrizol Corp., Vascular Biosciences,
and Viatris Inc.
|
Key Market Trends Fueling Growth
The QbD approach, a fact-based rational method, is gaining
popularity in the manufacturing of liposomal formulations.
Regulatory bodies are pushing for process harmonization, making QbD
an attractive choice. This approach enhances product quality,
gradation, and consistency of excipients, leading to superior final
products. The increasing adoption of QbD is expected to
significantly contribute to the growth of the liposomal products
market during the forecast period.
The liposomal products market is experiencing significant growth
due to the increasing demand for advanced delivery systems. These
systems, such as liposomes, offer improved therapeutic efficacy and
reduced side effects. The use of liposomes in delivering drugs and
nutraceuticals is gaining popularity, particularly in the areas of
cancer treatment, drug delivery, and nutritional supplements.
Producers are focusing on developing new liposomal products to
cater to this trend. The market is competitive, with companies
investing in research and development to produce innovative
liposomal products. The future looks promising for this market,
with a growing number of applications and potential for further
growth.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The Liposomal Products Market faces significant challenges due
to inadequate reimbursement policies for cancer treatments in
developed countries like the US. High out-of-pocket costs,
deductibles, premiums, and co-pays for medications are major
concerns. In developing economies, such as India and China, a large population lacks health
insurance coverage, making cancer treatment unaffordable. Late
diagnosis, limited healthcare expertise, and treatment facilities
further complicate matters. The high cost of cancer treatment and
out-of-pocket expenses remain the biggest barriers to accessing
care, hindering market growth in these regions.
- The Liposomal Products market faces several challenges in the
industry. Unilever and Nestle are key players in this field,
producing and distributing these innovative products. The use of
phospholipids and cholesterol in the production process is crucial
for creating effective liposomes. However, the high cost of
production and difficulty in scaling up the manufacturing process
pose significant challenges. Additionally, the need for proper
storage and handling to maintain the stability of these products is
essential. The regulatory environment also adds complexity, with
different regulations in various countries. Despite these
challenges, the market continues to grow due to the unique benefits
of liposomal products, such as increased bioavailability and
improved efficacy.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This liposomal products market report extensively covers market
segmentation by
- Application
- 1.1 Cancer
- 1.2 Fungal infections
- 1.3 Pain management
- 1.4 Viral vaccines
- 1.5 Photodynamic therapy
- Type
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Cancer- The liposomal products market is
experiencing steady growth due to the increasing demand for
advanced delivery systems in healthcare. These products, which
encapsulate active ingredients in lipid bilayers, offer improved
bioavailability and enhanced efficacy. Companies are investing in
research and development to expand their liposomal offerings,
catering to various therapeutic areas such as cardiovascular
diseases, cancer, and infectious diseases. The market is expected
to continue its expansion, driven by the benefits these innovative
formulations bring to patients.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Research Analysis
The Liposomal Products Market encompasses the production and
distribution of nanoscale lipid vesicles, including unilamellar
vesicles (small and large), oligolamellar vesicles, multilamellar
vesicles, and multivesicular liposomes. These spherical-shaped
vesicles are composed of phospholipid bilayers, primarily
consisting of glycerolphospholipid, sphingomyelin, and cholesterol.
Nanosizing techniques, such as methoxyPEG modification, are
employed to ensure optimal size and stability. Drug loading methods
are crucial quality attributions, enabling the encapsulation of
various drugs within these vesicles. Diffusion and cell fusion
processes are essential in the production and functionality of
these liposomal products. Notable drugs, such as amphotericin, are
effectively delivered using this technology. The Data Bridge serves
as a vital platform for market analysis and trends in the Liposomal
Products Market.
Market Research Overview
The Liposomal Products market refers to the sector that produces
and distributes liposomal formulations for various therapeutic
applications. These products are designed to enhance the
bioavailability and efficacy of active ingredients by encapsulating
them in lipid bilayers. The market is driven by the growing demand
for alternative drug delivery systems and the increasing prevalence
of chronic diseases. Technologies such as nanoliposomes, ethyl-PEG
liposomes, and pH-sensitive liposomes are used to develop these
products. The market is segmented based on application areas,
including cardiovascular diseases, cancer, infectious diseases, and
others. The market is expected to grow significantly due to the
advantages offered by liposomal products over traditional
formulations.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Application
-
- Cancer
- Fungal Infections
- Pain Management
- Viral Vaccines
- Photodynamic Therapy
- Type
-
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/liposomal-products-market-size-is-set-to-grow-by-usd-3-99-billion-from-2024-2028--rising-incidence-of-fungal-disorders-to-boost-the-market-growth-technavio-302184091.html
SOURCE Technavio